Trial Profile
To predict the senstivity of recurrence to Nivolumab senstivity from archived surgical specimen of primary tumor obtained at the time of initial surgery in patients with non small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer